Provention Bio, Inc. (PRVB) News

Provention Bio, Inc. (PRVB): $9.23

0.13 (+1.43%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PRVB to Watchlist
Sign Up

Industry: Biotech


Ranked

of 401

in industry

Filter PRVB News Items

PRVB News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

PRVB News Highlights

  • PRVB's 30 day story count now stands at 7.
  • Over the past 29 days, the trend for PRVB's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about PRVB are BIO, HTGC and LOAN.

Latest PRVB News From Around the Web

Below are the latest news stories about PROVENTION BIO INC that investors may wish to consider to help them evaluate PRVB as an investment opportunity.

Provention Bio Announces Closing of Second Tranche with Hercules Capital to Support U.S. Commercial Launch of TZIELD®

Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the close of the $40 million second tranche under the previously announced term loan facility of up to $125 million with Hercules Capital, Inc. (NYSE: HTGC), a leader in customized financing for companies in life sciences.

Yahoo | February 2, 2023

Should You Invest in Provention Bio (PRVB)?

Tourlite Capital Management, an investment management company, released its fourth-quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, Tourlite Fund Founder Class returned 3.4% compared to a 7.6% return for the S&P 500 Index. Since its inception in April 2022, the fund returned 5.0% compared to a -14.2% […]

Yahoo | January 24, 2023

Market Sentiment Around Loss-Making Provention Bio, Inc. (NASDAQ:PRVB)

Provention Bio, Inc. ( NASDAQ:PRVB ) is possibly approaching a major achievement in its business, so we would like to...

Yahoo | January 11, 2023

Provention Bio Inc. (NASDAQ:PRVB) Shares Plunged -12.50% In A Week – But Can It Maintain Its Gains?

In last trading session, Provention Bio Inc. (NASDAQ:PRVB) saw 1.15 million shares changing hands with its beta currently measuring 2.30. Company’s recent per share price level of $9.10 trading at $0.22 or 2.48% at ring of the bell on the day assigns it a market valuation of $780.69M. That closing price of PRVB’s stock is … Provention Bio Inc. (NASDAQ:PRVB) Shares Plunged -12.50% In A Week – But Can It Maintain Its Gains? Read More »

Marketing Sentinel | January 7, 2023

Provention Bio Announces the Grant of Inducement Awards

Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company granted stock options to 58 non-executive employees to purchase an aggregate of 763,000 shares of common stock. The stock options were granted without stockholder approval as inducements, material to the new non-executive employees entering into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4) a

Yahoo | January 6, 2023

Provention Bio Announces Appointment of Rita Jain, M.D., to Board of Directors

Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the appointment of Rita Jain, M.D., to the Company's Board of Directors. Dr. Jain is a biotechnology industry veteran with more than two decades of experience in pharmaceutical development across her time with ChemoCentryx, Inc., AbbVie, Abbott Laboratories, and G.D. Searle and Co. prior to the latter's merger with Pharmacia & Upjohn

Yahoo | January 5, 2023

Provention Bio Inc. (PRVB) Shares Are Up 72.06% So Far This Year

Provention Bio Inc. (NASDAQ:PRVB) has a beta value of 2.30 and has seen 1.53 million shares traded in the last trading session. The company, currently valued at $829.59M, closed the last trade at $9.67 per share which meant it lost -$0.9 on the day or -8.51% during that session. The PRVB stock price is -9.82% … Provention Bio Inc. (PRVB) Shares Are Up 72.06% So Far This Year Read More »

Marketing Sentinel | January 4, 2023

Provention Bio: Tzield Approved, But Neutral On Commercial Launch

Provention Bio''s Tzield approved by the FDA. Read more to see why we''re optimistic about PRVB stock but are on the sidelines for now.

Seeking Alpha | January 2, 2023

12 Best 52-Week High Stocks To Buy Now

In this article, we will take a look at the 12 best 52-week high stocks to buy now. If you want to see more stocks in this selection, go to the 5 Best 52-Week High Stocks To Buy Now. The equity markets have been taking a beating this year as the Dow Jones Industrial Average […]

Yahoo | December 29, 2022

12 Best Biotech Stocks to Buy Under $10

In this article, we discuss the 12 best biotech stocks to buy under $10. If you want to see more stocks in this selection, check out 5 Best Biotech Stocks To Buy Under $10. The past two years have been challenging for the biotech sector, based on the market performance of biotech equities. Compared to […]

Yahoo | December 28, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5949 seconds.